Many of you who follow my website or heard me on the "Conquering Your Pain" radio show are aware that one of the obstacles that we face is the lack of large-scale, high-quality published studies supporting the use of stem cell and platelet rich plasma injections (PRP), among other techniques in the treatment of painful conditions. In fact, if you go to a typical healthcare search engine such as PubMed, there are, in fact, many thousands of studies pertaining to regenerative medicine including stem cell therapy.
In general, all published medical research can be rated from Level I evidence (highest) to Level VII (lowest), based on things like design of the study including RCTs (randomized controlled trials), the number of patients enrolled, among other criteria*. However, even studies that are Level III - VII still count in the universe of published medical scientific research, especially if there are thousands of them!
It is not unusual for pharmaceutical companies to spend millions, or tens of millions of dollars, on a RCT study in the hopes of getting “blockbuster” drug approved by the FDA. Those of us working in the field of regenerative medicine, including platelet rich plasma and autologous mesenchymal stem cell, do not have the backing of “deep pockets” of a pharmaceutical or a medical device company. The people at big Pharma know that they cannot make any money off YOUR stem cells!
At Proliance Eastside Pain and Regenerative Medicine we believe in patient-centered evidence-based care and we have been tracking patient data since the very first stem cell/PRP procedure 8 years ago. Since that time, the number of patients treated have grown exponentially, which poses a problem as far as ongoing useful data collection.
In light of this, we are very pleased to announce a partnership with DataBiologics, a company that was started in 2019 by two doctors who were collecting their own “pencil and paper” patient data since 1995. Using the DataBiologics platform will generate longitudinal patient outcomes metrics for not only regenerative medicine/cellular based therapies, but also for alpha-2-macroglobulin, orthobiologics, Vertiflex, as well as other innovative treatments. Utilizing these metrics will provide clinical insights that will allow us to continually improve our patient care.
"Let patient outcomes drive meaningful clinical decisions" is the heading on one of the Databiologics web pages.
We could not agree more!
*For more information check out this Level of Evidence table.
Visit: Blogs | Podcasts | Podcast Archive